Alnylam, Medicines
cholesterol drug lasts months after one shot
Send a link to a friend
[August 31, 2015]
By Ben Hirschler
LONDON (Reuters) - A new drug in early
development cuts cholesterol as much as two potent injections recently
cleared for sale but lasts much longer, meaning it may need to be given
only every three to six months, initial findings suggest.
|
Results with Alnylam Pharmaceuticals and Medicines Co's experimental
product ALN-PCSsc highlight the competition for a market tipped to
generate billions of dollars in sales.
Unlike rival antibody-based PCSK9 medicines that work in the blood,
the new under-the-skin injection is a first-in-class treatment that
stops synthesis of the protein which is linked to "bad" LDL
cholesterol in the liver.
Targeting PCSK9 is a hot area for drug companies seeking to cut
heart risks for millions of people who don't benefit from
conventional statin drugs.
Amgen's Repatha and a rival product, Praluent, from Sanofi and
Regeneron Pharmaceuticals, are each expected to generate more than
$2 billion a year in sales by 2020, according to Thomson Reuters
data.
Pfizer also has a PCSK9 drug in late-stage trials, and is
experimenting with an oral pill.
![](http://archives.lincolndailynews.com/2015/Aug/31/images/ads/current/hartsburggrain_daily_sda_021115.png)
Alnylam and Medicines Co's product will be relatively late to the
party, as it is unlikely to go on sale before 2020 even if
subsequent late-stage studies are successful, but its reduced
injection frequency could make it an attractive option.
Results from 69 patients in a Phase I trial, reported at the
European Society of Cardiology (ESC) congress on Sunday, found a
single dose of 300 mg reduced LDL by just over 50 percent at 12
weeks, similar to the 50-60 percent seen with antibody drugs, and
the reduction was still 44 percent after 140 days.
"We're not quite sure exactly how long this stuff lasts but we know
it is more than 140 days for many patients," Medicines Co Chief
Executive Clive Meanwell told Reuters.
"The ability to control LDL cholesterol with an injection every
three to six months will mean patients can get their cholesterol
checked while doctors decide if they need another shot, which should
improve adherence."
[to top of second column] |
![](http://archives.lincolndailynews.com/2015/Aug/31/images/ads/current/cia_2_lda_031115.png)
ALN-PCSsc was generally well tolerated with no significant adverse
events, though bigger safety and efficacy studies are needed.
Medicines Co plans to start a Phase II study by end-2015 and a
final-stage Phase III trial by end-2017.
The new drug uses a novel approach known as RNA interference, or
gene silencing, to stop the synthesis of PCSK9, giving it the
ability to knock down the protein with an injection administered
once-quarterly or possibly bi-annually.
"It is a follower, but really it's more of a next-generation idea,"
said Meanwell.
Cost is a major issue for PCSK9 drugs, with Repatha and Praluent
priced at more than $14,000 a year, before discounts. Meanwell said
the new drug would probably be cheaper to make but its price would
be determined by the value it offered.
Jefferies analysts currently model peak ALN-PCSsc sales of $980
million, after applying a 50 percent risk discount because the drug
is still at an early stage.
Shares in Medicines Co and Alnylam rose 6 and 4 percent respectively
on Friday ahead of the ESC meeting.
(Reporting by Ben Hirschler; Editing by Ruth Pitchford)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
![](http://archives.lincolndailynews.com/2015/Aug/31/images/ads/current/topflight_west_sda_101414.png) |